873852-15-4

Basic information

• Product Name: Benzoic acid, 4-(2-ethoxy-2-oxoethoxy)-3-nitro-, methyl ester
• Synonyms: methyl 4-ethoxycarbonylmethyloxy-3-nitrobenzoate;Benzoic acid,4-(2-ethoxy-2-oxoethoxy)-3-nitro-,methyl ester
• CAS NO: 873852-15-4
• Molecular Formula: C12H13NO7
• Molecular Weight: 283.238
• Mol File: 873852-15-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(2-ethoxy-2-oxoethoxy)-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(2-ethoxy-2-oxoethoxy)-3-nitro-, methyl ester(873852-15-4)
• EPA Substance Registry System: Benzoic acid, 4-(2-ethoxy-2-oxoethoxy)-3-nitro-, methyl ester(873852-15-4)

Safety Data

• Hazardous Substances Data: 873852-15-4(Hazardous Substances Data)

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 616-82-0 3-nitro-4-hydroxybenzoic acid 
• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 758684-29-6 methyl 3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate 
• 604756-32-3 methyl 3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate 

Relevant articles and documents

The discovery of potent small molecule activators of human STING

The adaptor protein STING plays a major role in innate immune sensing of cytosolic nucleic acids, by triggering a robust interferon response. Despite the importance of this protein as a potential therapeutic target for serious unmet medical conditions inc

Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors

A series of novel morpholin-3-one-fused quinazoline derivatives were designed, synthesized and evaluated as EGFR tyrosine kinase inhibitors. Nineteen compounds showed significant inhibitory activities against EGFRwtkinase (IC50?wt(IC50?=?53.1?nM). Compound a7 and a8 showed excellent inhibitory activities against mutant EGFRT790M/L858Rand strong antiproliferative activity against H358 and A549 cell lines. Finally, molecular docking studies were performed to predict the possible binding mode of the target compounds. It is believed that this work would be very useful for designing a new series of tyrosine kinase inhibitors targeting EGFR.

3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.